Seattle Genetics drops under ASH cloud as PD-1s hog limelight
This article was originally published in Scrip
Executive Summary
Seattle Genetics saw its share price drop 7% on 8 December despite positive data presentations at the American Society of Hematology (ASH) annual meeting. Investors are concerned that Adcetris (brentuximab vedotin), which it is developing in collaboration with Takeda, will not fare well against competing therapies in Hodgkin lymphoma, namely the PD-1 drugs Merck & Co's pembrolizumab and Bristol-Myers-Squibb's nivolumab.